Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Q4 2025 results: EPS beats expectations, lenabasum Phase II hits primary endpoints, and the company’s pipeline shows potential for accelerated approval in U.S. and Europe—watch this high‑risk biotech’s progress.

Corbus Pharmaceuticals Holdings Inc has experienced significant stock price fluctuations and investor sentiment swings as it navigates the challenges of developing innovative therapeutic drugs for inflammatory and fibrotic diseases.